Results 91 to 100 of about 18,962 (231)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton +11 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim +9 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET ...
Zhuoran Yang +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess whether glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are associated with a lower incidence of age‐related ocular diseases in non‐diabetic older adults with overweight or obesity. Materials and Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX global research network.
Kuo‐En Chen +3 more
wiley +1 more source
Potential of liraglutide in the treatment of patients with type 2 diabetes
Vascular Health and Risk Management, 2009 Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type ...
Carolyn F Deacon
doaj
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen +10 more
wiley +1 more source
International Journal of Nanomedicine, 2017 Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences ...
Qi Q +9 more
doaj